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Both albuterol and nedocromil sodium have been recognized to possess certain anti-inflammatory properties. 
However, there are no data on the impact of these drugs on the pathophysiology of the bronchial extracellular 
matrix in asthma characterized by enhanced tenascin (Tn) expression, known to occur proportional to the severity 
of asthma. This paper reports data from a morphometric study on the effects of regular treatment with inhaled 
albuterol or nedocromil sodium on the extent of bronchial subepithelial deposition of Tn, collagen types III, IV, and 
VII and mucosal infiltration with macrophages. 
Thirty-two patients (14 women) with chronic asthma, aged 38.7 years (median) with a median forced expiratory 
volume in 1 set (FEV,) of 74.4% predicted, were selected to undergo fibre-optic bronchoscopy with bronchial 
biopsies before and after 12 weeks of treatment with either inhaled albutero10.2 mg or nedocromil sodium 4 mg four 
times daily according to a double-blind protocol. Cryostat sections of the biopsy specimens were studied by indirect 
immunostaining techniques using monoclonal antibodies and computer-assisted quantitative image analysis. 
Albuterol treatment significantly reduced the median thickness of subepithelial Tn expression from 9.7 to 6.3 pm 
(PzO.023) and macrophage numbers in the epithelium (P=O.O34), lamina propria (P=O.O39) and entire mucosa 
(P=O.O33), whereas nedocromil sodium had no effect. Expression of the collagen types was not affected by either 
treatment. There was no identifiable statistical difference between the two treatments for any of the outcome 
variables measured. Nevertheless, the results demonstrate that even a short-acting j&agonist may exert anti- 
inflammatory potential sufficient to interfere with the basic mechanisms of asthma as shown by reduction of 
subepithelial Tn content and mucosal macrophage count. 
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Introduction 
The recognition of chronic inflammation as the underlying 
pathological basis of asthma has advocated the regular use 
of anti-inflammatory therapy (1). Both &-adrenoreceptor 
agonists and nedocromil sodium are known to exert certain 
anti-inflammatory effects. However, based on available 
clinical experience and published information, various 
guidelines for asthma management (1,2) support the use of 
short-acting &-agonists for symptomatic relief on an 
as-needed basis only because tile regular administration of 
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these drugs has resulted in increased non-specific bronchial 
responsiveness (3), enhanced late response to inhaled aller- 
gen (4), loss of asthma control (5) and an increased risk of 
asthma death (5). Nevertheless, numerous studies have 
demonstrated that the &-agonists, in addition to directly 
inducing relaxation of bronchial smooth muscle and inhib- 
iting of vascular permeability, may also benefit patients 
with asthma by inhibition of release or synthesis of pro- 
inflammatory, profibrogenic, and spasmogenic mediators 
from the lung (6). This is achieved by their action at 
&adrenoreceptors on particular human cell types, result- 
ing in inhibited release of histamine, prostaglandins, and 
leukotrienes from mast cells (6), inhibited generation of 
tumour necrosis factor-u (TNF-a) (7) and interferon-y 
(IFNy) (8,9) by monocytes and B-lymphocytes, and 
depressed expression of platelet-derived growth factor 
(PDGF) mRNA from monocytes and alveolar 
macrophages (10). 
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On the other hand, nedocromil sodium, an anti- 
inflammatory agent without direct bronchodilating proper- 
ties, appears to be effective in ameliorating the clinical 
measures of asthmatic airway inflammation without 
significant side-effects (11) and is therefore recommended 
for daily treatment of mild persistent asthma (1). The 
anti-inflammatory activities of nedocromil sodium, a di- 
sodium salt of a pyranoquinoline dicarboxylic acid, have 
been suggested to relay on blocking cell membrane chloride 
channels (12). This leads to inhibition of mediator release 
from a range of cell types involved in the pathogenesis of 
asthma: eosinophils (13), T lymphocytes (14), B lym- 
phocytes (15), mast cells (16); monocytes (I 7) macrophages 
(17), platelets (17) and bronchial epithelial cells (18). 
A morphological approach, based on bronchial bi- 
opsies, provides the most reliable assessment of local 
pathophysiological processes at the site of asthmatic 
inflammation (19) as well as demonstrating the effects of 
drug therapy (20). Previously, we have shown a deposi- 
tion of heightened amounts of tenascin (Tn) in the sub- 
epithelial reticular basement membrane (BM) of asthma 
patients (21,22). The extent of Tn expression was propor- 
tional to the severity of asthma and could be reduced 
with inhaled corticosteroid treatment (22). Only a limited 
number of biopsy studies using albuterol or nedocromil 
sodium have been performed on asthma patients. In a 
16-week study by Manolitsas et al. (23) treatment with 
nedocromil sodium was associated with a decrease in 
airway infiltration with eosinophils, whereas an increase 
occurred among the albuterol-treated patients so that the 
change in eosinophil count was significantly different 
between the active treatments. Our recent 12-week trial 
also revealed a trend toward a decrease in the number of 
EG2-positive eosinophils with nedocromil sodium and an 
increase with albuterol, but without a statistical difference 
between the treatments (24). In contrast to the report of 
Manolitsas et al. (23) we demonstrated a significant 
reduction of T lymphocytes in the nedocromil sodium 
group, although without a concomitant change in the 
albuterol group (24). We were not able to detect any 
changes in mast cell numbers and, as in the study by 
Manolitsas et al. (23), no between-treatment differences 
were detected in lymphocyte and mast-cell numbers. 
As for macrophages, the impact of &agonists or 
nedocromil sodium on the inflammatory reaction of the 
airway extracellular matrix (ECM) with enhanced Tn 
content and collagen deposition remains unknown. In 
addition, a close association between macrophage-derived 
profibrogenic cytokines and the fibroproliferative response 
(25) which leads to subepithelial fibrosis and remodelling 
of the bronchial ECM makes the knowledge of the poten- 
tial effects of these drugs on airway macrophages a 
valuable adjunct in validation of their position in the 
management of asthma. Here, we report separately 
unpublished results obtained from our recently imple- 
mented protocol (24) in order to emphasize the effect of 
treatment with albuterol or nedocromil sodium on the 
subepithelial expression of Tn and collagen types and on 
mucosal macrophage numbers in patients with chronic 
asthma. 
Methods 
STUDY DESIGN 
The study was a part of our previously reported, random. 
ized, double-blind, group comparative study conducted as 2 
co-operative investigation between the Departments 01 
Medicine, University Central Hospital, Helsinki, Finland 
and University of Tartu, Estonia (24). Briefly, the protocol 
included patients of either gender, aged 18 years or older, 
with an established diagnosis of asthma for at least 6 
months. Entry criteria required the presence of asthma 
symptoms of a certain severity, defined as a total symptom 
score of at least 10 for any 10 days during a 2-week baseline 
period. The total symptom score was defined as the sum of 
four symptoms, including daytime symptoms, night-time 
symptoms, morning chest tightness and cough, each rated 
on a five-point scale (from O=absence of symptoms to 
4=very severe). All patients had to have a provocative dose 
causing a reduction of 15% in forced expiratory volume in 
1 set (FEV,) (PD,,FEV,) of less than 1.6 mg histamine 
to verify their bronchial hyper-responsiveness (26). In 
addition, each patient had to demonstrate reversibility of 
airways obstruction of at least 15%, measured by FEV, 
in response to an inhaled bronchodilator. Alternatively, 
patients were required to have documented evidence of at 
least 20% variability in peak expiratory flow rate (PEFR) 
taken daily over a 7-day period. Systemic or inhaled 
corticosteroids, nedocromil sodium, ketotifen and oral 
bronchodilators were withdrawn 6 weeks before entry into 
the trial. 
After a 2-week baseline period, during which the patients 
were continued on their allowed therapy, eligible patients 
were randomized using computer-generated sequentially 
coded study numbers to receive either 4 mg nedocromil 
sodium (2 mg dose - i, two inhalations) four times daily 
(q.i.d.), or 0.2 mg albuterol (0.1 mg dose- ‘, two puffs; 
Ventolinem, Glaxo Operations, London, U.K.) q.i.d. for the 
next 12 weeks. Both drugs were provided by Fisons Plc. 
(Loughborough, Leicestershire, U.K.) and delivered from 
coded metered dose inhalers. 
Patients visited the clinic at the start of the baseline 
period, at randomization and 4, 8 and 12 weeks after 
treatment. Bronchial biopsies were taken at the beginning 
and end of treatment (at visits 2 and 5). On each visit, the 
investigator examined the patient and checked his or her 
inhalation technique to ensure adequate delivery of the 
study drug. Patient compliance was assessed by having 
patients record their use of the test medication on the diary 
card and by weighing the returned aerosol canisters. 
During the treatment phase, all patients had access to 
rescue therapy with inhaled albuterol (O,l mg dose-‘) on 
an as-needed basis. Other permitted medications included 
oral prednisolone, oral or intravenous bronchodilators, 
antihistamines and antibiotics. If oral prednisolone was 
needed, according to protocol, it was given at a daily 
starting dose of 30 mg, followed by a decrease in dose of 
5 mg each day. Antihistamines, nasal disodium cromo- 
glycate (Lomudal Nasal@, Fisons) and nasal corticosteroids 
were allowed to control allergic rhinitis. The use of all 
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concomitant medications other than as-needed inhaled 
albuterol was not permitted for longer than 12 days on two 
occasions during the trial. All concomitant medications 
were recorded by the patients on the diary card. 
The research protocol was approved by institutional 
ethical review committees at both centres, and all patients 
provided written informed consent. 
BRONCHOSCOPY AND BRONCHIAL BIOPSIES 
Bronchoscopic examination and collection of biopsy 
samples conformed to the international guidelines for inves- 
tigative use of fibre-optic bronchoscopy in asthma and 
other airway diseases (27). All patients were premeditated 
with intravenous atropine sulphate 0.5-l mg and diazepam 
5-10 mg. After local anaesthesia of the oropharynx and 
vocal cords with lidocaine spray (Xylocain@, Astra Draco 
AB, Siidertalje, Sweden) and lidocaine 2% solution (Orion 
OY, Espoo, Finland), an Olympus BF-20 fibre-oscope 
(Olympus Optical Co., Tokyo, Japan) was introduced into 
the right bronchial tree, where the bronchi were anaesthe- 
tized with lidocaine 2% solution instilled through the bron- 
choscope channel. Three bronchial biopsies were taken by 
the same bronchoscopist at each bronchoscopy: one from 
the right middle and two from the right upper lobe bronchi. 
The regions very close to carinae and those previously 
touched by the bronchoscope were avoided. At the post- 
treatment bronchoscopy, the particular biopsy sites utilized 
at the pre-treatment bronchoscopy were also avoided. All 
specimens were obtained with Olympus FB-19C forceps. 
LABORATORY METHODS 
Sample processing and immunohistochemistry 
Biopsy specimens were immediately snap-frozen in liquid 
nitrogen (Estonian Academy of Science, Tartu, Estonia) 
and stored at - 70°C until sectioned. After embedding in 
Tissue Tek ornithyl-carbamyltransferase (O.C.T.) medium, 
5;um serial sections were cut on a Leitz 1720 Digital 
Cryostat (Ernst Leitz GmbH, Wetzlar, Germany). Immu- 
nostaining with a mouse monoclonal antibody (mAb) 
lOOEB2 reacting with the fourth and fifth fibronectin-like 
domains in Tn-C molecule (28) was used to detect Tn. An 
IgG2a mAb against human type III collagen (150, HEYL 
Vertriebs GmbH, Iserlohn, Germany), an IgG2b mAb 
which recognizes human type IV collagen (1:50, Boehringer 
Mannheim GmbH, Mannheim, Germany), and an IgGl 
mAb against the carboxy-terminus and the major helical 
domain of human type VII collagen (1:lOOO Gibco BRL, 
Gaithersburg, MD, U.S.A.) were applied to label the 
respective collagen types. The sections were fixed in pre- 
cooled acetone at - 20°C for 10 min, exposed first to the 
primary mAb at room temperature for 30 min, washed in 
phosphate-buffered saline (PBS) and exposed to 1:50 
diluted fluorescein isothiocyanate (FITC)-conjugated sheep 
anti-mouse IgG (Jackson Immunoresearch Laboratories, 
West Grove, PA, U.S.A.). Finally, the sections were 
mounted in sodium-veronal-buffered glycerol (1: 1, pH 8.4) 
and examined under a Leitz Aristoplan fluorescence micro- 
scope equipped with an appropriate filter system for FITC 
fluorescence. In order to label macrophages, the mAb 
Ber-MAC3 (1:50, Dako A/S, Glostrup, Denmark) was 
used. This mAb recognizes CD163, a 130-kDa macrophage- 
associated integral membrane protein of the scavenger 
receptor superfamily, and enables distinguishing tissue 
macrophages from non-activated monocytes, starry sky 
macrophages, epithelioid macrophages, and multinucleated 
macrophages (29,30). Before our core experiments, the 
reactivity of this antibody was tested on cryosections of 
peripheral lung where it was supposed to stain alveolar 
macrophages. After fixation in acetone at room tempera- 
ture for 10 min, the samples were exposed to the primary 
antibodies for 30 min and then processed by the alkaline 
phosphatase anti-alkaline phosphatase technique (Dako). 
The specific immunoreactivity was visualized by using a 
substrate solution containing naphthol AS-B1 phosphate, 
levamisole, and new fuchsin (all from Sigma Chemical Co., 
St. Louis, MO, U.S.A.) reacted with sodium nitrite (E. 
Merck, Darmstadt, Germany). Finally, the slides were 
mounted in Dako Glycergel and examined under a Leitz 
Dialux 22 EB light microscope. 
Quantification of the results 
As previously described (21,22) for quantitating ECM 
proteins, the cross-sections of the BM area containing 
positive immunoreactivity were photographed with Kodak 
T-MAX 400/800 black-and-white film (Eastman Kodak 
Co., Rochester, NY, U.S.A.) at a preliminary magnification 
of x 80 with care to avoid sections where the BM zone was 
not cut perpendicularly. Paper photocopies were repro- 
duced to reach the final magnification of x 643 for Tn and 
type III collagen and x 1310 for type IV and VII collagen. 
The ECM proteins were quantified by semiautomatic 
drawing of the margins of specifically stained areas of the 
BM from photomicrographs with a properly calibrated 
Kurta IS/THREE digitizing tablet (Kurta Corp., Phoenix, 
AZ, U.S.A.) and a pointing device linked to a computer. 
With use of the Autocad program, version lO.On, 
(Autodesk Inc., Sausalito, CA, U.S.A.), minimal distances 
were calculated between each point on the superficial limit 
and the closest point on the deeper border of the specific 
immunoreactivity in the BM. The mean value was consid- 
ered as the thickness of expression of the ECM protein. 
Mucosal macrophages were counted using the method we 
recently reported for quantitating eosinophils, mast cells 
and T lymphocytes (24). Briefly, the cells were counted 
from the whole biopsy sections photographed on Kodak 
EPN 100 colour slide film and projected without image 
distortion onto a Kurta digitizing tablet to reach a magni- 
fication of x 695. The photomicrograph images containing 
the bronchial epithelium and lamina propria (LP) with the 
specifically stained macrophages were charted using the 
pointing device. Areas where tissue was stretched, squeezed 
or double-folded were excluded. Macrophage densities were 
first calculated separately in the epithelium and LP with the 
Autocad program and then pooled to express the results 
for the entire mucosa as well (as cell counts per square 
millimeter). 
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TABLE 1. Patient demographic characteristics 
Characteristic 
Nedocromil Salbutamol 
sodium group group 
(n=16) (n=16) 
Age (years)* 
Sex (men/women) 
Duration of asthma (years)* 
Asthma severity 
Aas .5-point scale score? 
Mild/moderate/severe/very severe 
Presence of atopyl 
Presence of seasonal variation (from case histories) 
Asthma medication in past year 
Inhaled &agonists 
Theophylline 
Forced vital capacity (% predicted)* 
FEV, (% predicted)* 
PD,, (FEV,) (mg histamine)* 
45.6 (23,6-57.2) 35.7 (19.0-58.3) 
1016 8/8 
5.0 (244) 7.5 (l-30) 
2.0 (14) 2.0 (l-2) 
5/10/O/l 6/l O/O/O 
6 10 
6 6 
16 14 
6 7 
100.7 (62-124) 95.0 (77-165) 
75.0 (32-104) 74.0 (41-122) 
0.03 (0.03-0.52) 0.04 (0.03-0.5) 
*Values are medians, and range in parentheses. 
tFrom (31). 
$Determined by skin-prick testing with 12 common allergen extracts. 
For proper calibration of the tablet, a microscopic scale 
was photographed and reproduced at the same magnifica- 
tions as applied to the sections. All measurements were 
performed at the Department of Anatomy, University of 
Helsinki, Finland, by the same analyser, who was blinded 
to the origin of the specimens or treatment status. 
STATISTICAL ANALYSIS 
Before comparisons, the distributions of all variables were 
tested for normality with the Shapiro-Wilk test. Due to the 
relatively low number of patients in the groups and the 
skewed distribution of the data, resulting in a sufficiently 
high proportion of variables in which the hypothesis of 
normal distribution was to be rejected, non-parametric 
statistics were used. The Mann-Whitney U-test was applied 
to differences between the treatment groups. Changes 
within groups (post-treatment vs. pre-treatment) were 
tested using Wilcoxon’s signed-ranks test for matched pairs. 
For each patient, the use of the rescue medication was 
expressed as the mean number of daily doses of the 14 
baseline days and the 14 days prior to each visit up to the 
end of the study. All statistical hypothesis tests were 
two-tailed and a value of P~0.05 was taken as significant. 
All analyses were performed using the SPSS package, 
version 4.0 (SPSS Inc., Chicago, IL, U.S.A.). 
Results 
PATIENTS 
Thirty-two adult patients, aged between 19 and 58 years 
and with an established diagnosis of asthma with a duration 
from l-44 years (median 5.5 years), were included in the 
study. None of the patients had received inhaled steroids or 
regular systemic steroids during the previous year. Instead, 
the patients were maintained on as-needed &agonists 
alone or in combination with long-acting theophyllines 
(Table 1). The two treatment groups were considered 
similar for former use of asthma medication, as well 
as all demographic, baseline clinical and histological 
variables. Sixteen patients were atopic, as determined by 
skin-prick testing with 12 common allergen extracts (ALK, 
Allergologisk Laboratorium A/S, Harsholm, Denmark). 
Most patients had mild or moderately severe asthma (11 
and 20 patients, respectively), as assessed by a specialist in 
pulmonary medicine on the Aas five-point scale (31). 
The patients demonstrated 15-104% (median 24.3%) 
reversibility of FEV, in response to inhalation of 0.2 mg 
albuterol. 
Two patients in the nedocromil sodium group and three 
in the albuterol group withdrew after randomization. Rea- 
sons for withdrawal in the nedocromil sodium group were 
failure to comply with the protocol and worsening of 
asthma resulting in use of disallowed medication. In the 
albuterol group, patients withdrew because of worsening of 
asthma, laboratory values significantly outside the normal 
range and lack of compliance with the protocol. The 
patients who withdrew from the study did not differ 
demographically from those who completed the study. 
Of those who completed, none received allowed corticoster- 
oids in any form or nasal disodium cromoglycate 
during the entire treatment period. Rescue medication 
with albuterol was used equally in both groups 
throughout the study and no significant changes occurred 
in rescue albuterol consumption within any group 
(Table 2). 
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TABLE 2. The use of rescue medication during the study in albuterol (n= 16) and nedocromil sodium 
(n=16) groups (doses day-‘)* 
Baseline Week 4 Week 8 Week 12 Change P-valuet 
Albuterol 3.58 2.46 2.00 0.58 0.97 0.13 
Nedocromil sodium 3.75 2.82 3.29 4.02 2.95 0.31 
P-value? 0.55 0.51 0.38 0.09 0.15 
*Presented as medians of variables. For each patient, the use of rescue medication was expressed as 
the mean number of daily doses of the 14 baseline days and the 14 days prior to each following visit. 
TAnalysed between groups by the two-tailed Mann-Whitney U-test. 
IAnalysed within groups between trial end and baseline using Wilcoxon’s signed-ranks test. 
MORPHOLOGY AND MORPHOMETRY OF 
BRONCHIAL BIOPSIES 
All bronchial biopsy specimens were of sufficient quality for 
assessment of Tn expression. In all specimens stained for 
Tn, an intense immunoreactivity associated with the BM 
zone could be seen, which continued deeper and joined with 
staining of connective tissue in the LP. Positive staining was 
also present in the bronchial epithelium, blood vessels, and 
smooth muscle. With regard to the distribution of Tn, no 
visual differences were observed either between the speci- 
mens obtained over the course of treatment within each 
group or between those from the nedocromil sodium- and 
albuterol-treated patients at the trial end. However, quan- 
titative analysis revealed that the thickness of subepithelial 
Tn expression decreased significantly (P=O.O23) with 
albuterol treatment (Fig. 1; Table 3). The two treatments, 
however, did not show significantly different changes in Tn 
expression. 
Diffuse immunoreactivity for type III collagen was 
localized in the entire BM and continued to the LP, 
where the staining pattern was more reticular and 
clearly distinguishable from that visible in the BM. The 
thickness of the collagen type III layer in the BM 
did not change significantly during treatment within 
either group when compared with pre-treatment values. 
Immunostaining for collagen types IV and VII was 
seen at the superficial margin of the subepithelial BM. In 
addition, immunoreactivity for type IV collagen was 
detectable in vessels, smooth muscle cells and the BM of 
bronchial glands. In almost all specimens, dot-like 
bodies positive for collagen type IV, suggestive of the 
anchoring plaques, were present close to the bottom of the 
linear subepithelial deposition. The thickness of both 
collagen types IV and VII was not affected by treatment 
(Table 3). 
The macrophage count decreased significantly in the 
epithelium (P=O.O34), LP (PzO.039) and entire mucosa 
(PzO.033) when patients were treated with albuterol (Fig. 
2). No significant changes occurred in the nedocromil 
sodium group. The two treatments did not differ signifi- 
cantly with regard to changes in macrophage number in 
either the epithelium, LP or entire mucosa. 
Discussion 
The results of this immunohistochemical study have shown 
for the first time that treatment with the short-acting 
&agonist albuterol significantly diminishes the thickness of 
the subepithelially located Tn layer and reduces the number 
of macrophages infiltrating the airways of patients with 
chronic asthma. Tn, a large ECM glycoprotein, is known to 
exert an enhanced expression in tissues during inflamma- 
tion and tissue repair (32,33). Increased subepithelial Tn 
deposition has been demonstrated in the bronchi of patients 
with different types of asthma, in proportion to the severity 
of the disease (21,22). In addition, the thickness of the 
0’ I I I I I 
Before After Before After 
FIG. 1. Effect of treatment with albuterol or nedocromil 
sodium on the thickness of the subepithelial layer of 
tenascin in bronchial biopsies taken before and after 12 
weeks of treatment. The difference between the two treat- 
ments did not reach statistical significance. Wilcoxon’s 
signed-ranks test was applied to evaluate the significance 
of changes within groups and the Mann-Whitney U-test 
to estimate the between-treatment differences. Values 
shown are for individual patients. Bars, median values. 
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TABLE 3. Changes in thickness of subepithelial immunoreactivity for tenascin and collagen types 111, 
IV, and VII &m) in albuterol (n= 13) and nedocromil sodium (n= 14) groups* 
Baseline Week 12 Change P-value8 
Tenascin 
Albuterol 
Nedocromil sodium 
Median difference 
95% CI 
P-value? 
Type III collagen 
Albuterol 
Nedocromil sodium 
Median difference 
95% CI 
P-value? 
Type IV collagen 
Albuterol 
Nedocromil sodium 
Median difference 
95% CI 
P-value? 
Type VII collagen 
Albuterol 
Nedocromil sodium 
Median difference 
95% CI 
P-value? 
9.74 6.34 - 1.58 0.02 
8.76 7.17 - 1.92 0.64 
0.93 - 1.31 - 2.24 
- 1.46, 3.34 - 2.78, 0.88 - 4.78, 1.43 
0.52 0.16 0.30 
8.98 9.58 0.23 0.70 
8.78 9.80 0.85 0.68 
- 0.01 - 0.36 - 0.71 
- 1.52, 1.56 - 1.83, 1.64 - 3.15, 2.49 
0.98 0.58 0.72 
2.28 1.80 - 0.23 0.09 
2.29 2.19 0.03 0.51 
0.02 - 0.39 - 0.36 
- 052, 0.33 - 0.70, - 0.06 - 0.78, O-07 
0.91 0.01 0.07 
2.67 3.01 0.37 0.08 
3.48 3.36 0.38 0.43 
- 0.76 - 0.40 0.25 
- 1.44, - 0.06 - 1.27, 0.51 - 0.64, 1.27 
0.11 0.33 0.65 
*Values are medians; CI; confidence interval. 
TAnalysed between groups by the two-tailed Mann-Whitney U-test. 
fAnalysed within groups using Wilcoxon’s signed-ranks test. 
subepithelial Tn layer has been shown to diminish signifi- that the decrease in Tn thickness and decline in macrophage 
number are related events, where Tn downregulation is 
secondary to macrophage decrease and inactivation by 
albuterol. The importance of the decreased macrophage 
numbers may also be related to the role of these cells as a 
potential source of profibrogenic cytokines, which cause the 
enhanced elaboration of interstitial collagens and sub- 
epithelial fibrosis characteristic of asthma (38). Although 
significant effect was found on the expression of the 
collagen types with either drug, the present results for 
Tn and macrophage count support the possibility that 
treatment with albuterol suppresses, to some extent, the 
fibroproliferative response and postpones airway ECM 
remodelling in asthma. 
cantly in response to treatment with inhaled corticosteroids 
(22). To date, neither a direct nor an indirect action of a 
&adrenoreceptor agonist on Tn synthesis or degradation 
has been described, in contrast to the effect demonstrated 
experimentally with corticosteroids (34). Nevertheless, 
albuterol inhibits various cell types which secrete pro- 
inflammatory cytokines. It has been shown to suppress 
both the release of IFN-1, (8;9) and TNF-a (7) from human 
blood mononuclear cells and the enhanced expression of 
PDGF mRNA by alveolar macrophages and adherent 
monocytes (10). These cytokines are widely expressed in 
the airways of asthma patients and function as a part of 
the complex cytokine network, which maintains chronic 
asthmatic inflammation. The fact that these cytokines also 
operate as Tn production stimulators (35-37) provides one 
explanation as to how treatment with albuterol may pro- 
duce a decrease in the level of Tn expression in asthmatic 
airways. Analogously, the decrease in macrophage numbers 
found in all tissue compartments when patients were treated 
with albuterol may be explained by suppression by the drug 
via the release of cytokines, particularly IFN-y, to the site 
of inflammation. On the other hand, the fact that the 
macrophages are themselves a major source of cytokines 
responsible for Tn upregulation (25) raises the possibility 
In this study, the reduction of subepithelial Tn and 
macrophage numbers by albuterol treatment conflicts with 
the results obtained for EG2-positive eosinophils, mast 
cells and T lymphocytes (24), which showed a significant 
decrease in T lymphocyte number in the nedocromil 
sodium-treated group. This evidence suggests that albuterol 
and nedocromil may either downregulate different cytokine 
profiles or suppress certain cytokines to a different extent, 
resulting in their exertion of inhibitory effects on different 
inflammatory cells or markers in asthma. Also, in context 
with the lack of changes in subepithelial Tn in the 
AIRWAY SUBEPITHELIAL TENASCIN IN ASTHMA 45 1 
Albuterol 
P = 0.03 + t Nedocromil sodium P = 0.20 . . 
2oot 
Before After Before After 
/ 
P = 0.04 P = 0.55 
2 800 
m 
s 
$j 600 
2 
: 400 
.5 
E 
2 200 : 
Before After 
4 t 
Before After 
P = 0.03 P = 0.16 
. c 
‘E E 800 t 
Before After 
FIG. 2. Effect of treatment with albuterol or nedocromil 
sodium on macrophage counts in the bronchial epi- 
thelium, lamina propria and entire mucosa in bronchial 
biopsies taken before and after 12 weeks of treatment. 
Differences between the two treatments did not reach 
statistical significance. The Mann-Whitney U-test was 
used to estimate the between-group differences, and 
Wilcoxon’s signed-ranks test was applied to the changes 
within groups. Values shown are for individual patients. 
Bars, median values. 
nedocromil sodium group analogous to those which 
occurred with albuterol treatment, or the inability of either 
drug to affect the collagens, one could speculate that this 
may be due to an insufficient inhibitory capacity of the drug 
to limit the release of profibrogenic or pro-inflammatory 
mediators by different cells. Another possible explanation is 
the treatment phase duration which was insufficient for 
significant change to become apparent. 
Given that both nedocromil sodium and &- 
adrenoreceptor agonists have certain effects associated with 
exertion of anti-inflammatory potential in asthmatics, the 
study was designed to compare only the two treatment 
regimens for their ability to reduce Tn thickness or macro- 
phage count without involving a placebo group for refer- 
ence. In a previous biopsy report (23) comparing the effects 
of albuterol, nedocromil sodium and placebo, the authors, 
despite finding nedocromil sodium superior to albuterol in 
the reduction of eosinophilia, did not detect any difference 
between the active treatments and placebo for eosinophil, 
mast cell or T-lymphocyte numbers. This lends support to 
the position that omitting the placebo group does not 
interfere substantially with the interpretation of the major 
factors behind our results in the present study. Although 
not revealing any significant differences between the 
albuterol and nedocromil sodium groups, this is the first 
study of the effects of these two treatments on Tn in 
asthma. It was therefore hard to perform calculations to 
determine the optimal duration of treatment, sufficient 
number of participating patients or their asthma severity as 
an inclusion criterion. In this study, the relatively small 
number of patients in both groups and the skewed distri- 
bution of data, necessitating the use of non-parametric 
statistics, may have been associated with insufficient stat- 
istical power to detect changes caused by both treatments. 
The present results are unlikely to have been biased by 
concomitant treatment with rescue albuterol or corticoster- 
oids as the use of rescue medication was relatively low and 
similar in both groups and as steroids had not been used 
regularly for 1 year prior to the start of trial and were not 
used by the patients in any form during the study. The use 
of steroids was similar in both groups. Another concern is 
that, because the majority of patients had had asthma for 
more than 5 years, it is probable that the effects of the 
short-acting &agonist albuterol and nedocromil sodium 
on the ECM may, in part, have remained masked by 
characteristic airway structural remodelling. This being the 
case, the lack of effects of nedocromil sodium on histologi- 
cal variables noted in the current study needs to be con- 
firmed by more extensive investigations. Principally, the 
relatively high macrophage numbers currently found in 
both the epithelium and LP, compared to our former results 
using electron microscopy in patients with newly detected 
asthma (19,20), could provide excellent scope for reduction 
by any of the study drugs. These high pretreatment macro- 
phage counts seem to be true because the epitheliall 
submucosal macrophage ratio was roughly similar to that 
found in previous reports (19,20) and the numbers 
expressed for the entire mucosa are in keeping with the 
results of other immunohistological studies (22,39). 
There were no statistically significant differences between 
the effects of either regularly administered albuterol or 
nedocromil sodium on any of the outcome variables studied 
here. In the light of the reasons discussed above, it remains 
possible that differences between the active treatments or 
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those versus placebo would become apparent in studies 
with greater power based on a longer treatment period and 
larger and more homogeneous groups of patients. Never- 
theless, the primary evidence from this study does not 
support the concept of nedocromil sodium as an effective 
anti-inflammatory drug and urges some caution in the 
recommendation of its use as basic anti-inflammatory 
therapy for asthma, although the recent guidelines laid out 
in the Global Initiative for Asthma (1) recommend 
inhaled nedocromil sodium for the daily treatment of mild 
persistent asthma. 
In conclusion, the results of this immunohistochemical 
study complement the current knowledge of the spectrum 
of action of the short-acting &agonist albuterol. The 
significant reduction of bronchial Tn expression and sup- 
pression of mucosal infiltration with macrophages found 
during albuterol treatment indicate that the drug is not only 
a directly acting bronchodilator, but may also interfere 
with the basic inflammatory mechanisms in asthma. This 
study also suggests a need for further investigation of the 
effects of nedocromil sodium on the airway ECM and 
inflammatory cells. 
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